The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.

RL Bates; S J Payne; S L Drury; P N Nelson; D A Isenberg; J J Murphy; G Frampton

doi:10.1191/0961203303lu436oa

The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.

RL Bates, S J Payne, S L Drury, P N Nelson, D A Isenberg, J J Murphy, G Frampton

The Rowett Institute of Nutrition and Health

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodiesin patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodiesas compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus

Original language	English
Pages (from-to)	617-622
Journal	Lupus
Volume	12
Issue number	8
Early online date	1 Aug 2003
DOIs	https://doi.org/10.1191/0961203303lu436oa
Publication status	Published - Aug 2003

Access to Document

10.1191/0961203303lu436oa

Cite this

@article{4e592900570446169ab96b807725b482,

title = "The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.",

abstract = "We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodiesin patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodiesas compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus",

author = "RL Bates and Payne, {S J} and Drury, {S L} and Nelson, {P N} and Isenberg, {D A} and Murphy, {J J} and G Frampton",

year = "2003",

month = aug,

doi = "10.1191/0961203303lu436oa",

language = "English",

volume = "12",

pages = "617--622",

journal = "Lupus",

issn = "1477-0962",

publisher = "SAGE Publications Ltd",

number = "8",

}

TY - JOUR

T1 - The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.

AU - Bates, RL

AU - Payne, S J

AU - Drury, S L

AU - Nelson, P N

AU - Isenberg, D A

AU - Murphy, J J

AU - Frampton, G

PY - 2003/8

Y1 - 2003/8

N2 - We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodiesin patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodiesas compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus

AB - We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodiesin patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodiesas compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus

UR - http://europepmc.org/abstract/med/12945721

U2 - 10.1191/0961203303lu436oa

DO - 10.1191/0961203303lu436oa

M3 - Article

C2 - 12945721

SN - 1477-0962

VL - 12

SP - 617

EP - 622

JO - Lupus

JF - Lupus

IS - 8

ER -

The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this